Hormone Therapy for Female Dog Incontinence Product Description INCURIN Tablets are FDA-approved estriol tablets formulated to control estrogen-responsive urinary incontinence in spayed female dogs. Each tablet contains 1 mg of estriol and is administered once daily with dose adjustments based on response. This short-acting natural estrogen helps improve urethral muscle tone while limiting long-term estrogenic risks. Prescription required. Benefits Controls Urinary Leakage: Indicated to manage estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. Improves Urethral Tone: Estriol increases resting urethral muscle tone to support bladder control in affected dogs. Flexible Dosing Plan: Dose is not weight-based and can be reduced stepwise to determine the lowest effective amount. Short-Acting Estrogen: Short receptor occupancy time limits prolonged estrogen exposure compared to other estrogens. Clinically Proven Effectiveness: Demonstrated statistically significant improvement over placebo in controlled field studies. Ingredients Composition Table Ingredient Quantity Estriol 1 mg per tablet How to Use Recommended-Dosage Chart Stage Dosage Frequency Duration Initial Therapy 2 mg Once daily Minimum 14 days First Reduction 1 mg Once daily After control achieved Further Reduction 0.5 mg Once daily Based on response Maintenance Option Determined lowest effective dose Every other day After stabilization Maximum Dose 2 mg Once daily Do not exceed Dosage & Administration Instructions Initial Dose: Administer 2 mg orally once daily for a minimum of 14 days. Stepwise Reduction: Decrease dose gradually to 1 mg or 0.5 mg once daily after continence is achieved. Adjustment Interval: Allow at least seven days between each dose adjustment to assess response. Maximum Limit: Do not administer more than 2 mg per dog per day. Diagnosis Review: Reassess diagnosis if no response is observed at a 2 mg daily dose. Prescription Required: Federal law allows this drug to be used only by a licensed veterinarian or with their prescription. Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet. Additional Information Precautions Evaluate Underlying Causes: Assess contributing factors of urinary incontinence before initiating treatment with INCURIN Tablets. Avoid Other Estrogens: Do not use concurrently with other estrogen products, as safety has not been evaluated. Liver Disease Caution: Use has not been evaluated in dogs diagnosed with liver disease. Not For Intact Dogs: Safety not established in intact females, pregnant, lactating, male, or dogs under one year. Possible Side Effects Digestive Effects: Dogs may lose their appetite, vomit, or drink more water during treatment. Vulvar Changes: Swelling, vaginal inflammation, or excessive licking of the vulva may occur. Behavioral Changes: Some dogs may show anxiety, aggression, overactivity, or sleepiness. Mammary Changes: Enlarged mammary glands have been seen in clinical and long-term studies. Hair Loss: Some dogs have experienced hair loss, either in specific areas or all over, based on post-market reports. Storage Information Room Temperature Storage: Store at or below 25°C or 77°F under normal conditions. Excursion Allowance: Temperature excursions permitted up to 40°C or 104°F. Shipping & Return We offer ground, express, priority, and international delivery; see our shipping policy for details. For return instructions or product concerns, please refer to our detailed refund policy. Prescription items are NON-RETURNABLE and NON-REFUNDABLE. Frequently Asked Questions Q1: What is INCURIN used for in dogs? Ans: INCURIN® Tablets are designed to help manage urinary incontinence in spayed female dogs caused by estrogen deficiency. They work by controlling leakage that can occur after spaying and are specifically approved by the FDA under NADA 141-325 for this purpose. Q2: How long does it take for INCURIN to start working? Ans: In a placebo-controlled field study, treatment success was evaluated after 14 days of once daily 2 mg dosing. A statistically significant improvement compared to placebo was observed at Day 14, indicating a response may be seen within two weeks of therapy. Q3: What is the recommended starting dose of INCURIN? Ans: All dogs should receive an initial dose of 2 mg once daily for a minimum of 14 days. The dose is not based on body weight. After urinary control is achieved, the dosage may be reduced stepwise to determine the lowest effective dose. Q4: What are the possible side effects of INCURIN in dogs? Ans: Reported side effects include loss of appetite, vomiting, swollen vulva, vaginal inflammation, tiredness, enlarged mammary glands, and changes in behavior. After the product was on the market, hair loss and rare blood changes were also reported. In clinical studies, side effects usually increased with higher doses. Q5: Is INCURIN safe for all female dogs? Ans: The safe use of INCURIN has not been evaluated in intact females, pregnant or lactating dogs, male dogs, or dogs under one year of age. It has also not been evaluated in dogs with liver disease or when used with other estrogens.
